AU Patent

AU2012203789B2 — Milnacipran for the long-term treatment of fibromyalgia syndrome

Assigned to Forest Laboratories Holdings ULC · Expires 2014-12-11 · 11y expired

What this patent protects

The present invention is directed to methods for providing long-term treatment of fibromyalgia syndrome (FMS) by administering a dual re-uptake inhibitor to a patient 5 with FMS. More particularly, the present invention is directed to the long-term treatment of FMS by administeri…

USPTO Abstract

The present invention is directed to methods for providing long-term treatment of fibromyalgia syndrome (FMS) by administering a dual re-uptake inhibitor to a patient 5 with FMS. More particularly, the present invention is directed to the long-term treatment of FMS by administering a norepinephrine-serotonin inhibitor (NSRI) to a patient with FMS.

Drugs covered by this patent

Patent Metadata

Patent number
AU2012203789B2
Jurisdiction
AU
Classification
—
Expires
2014-12-11
Drug substance claim
No
Drug product claim
No
Assignee
Forest Laboratories Holdings ULC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.